P684: PHASE 1 STUDY OF LP-108, A SELECTIVE BCL-2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA. (23rd June 2022) - Xu, W.; Feng, R.; Wang, L.; Song, Y.; Zhu, H.; Fan, L.; Guo, X.; Wei, X.; Lin, N.; Xu, C.; Wang, Z.; Xiao, X.; et al.